Remissions after long-term use of romiplostim for immune thrombocytopenia.
作者信息
Marshall Ariela L, Scarpone Roberta, De Greef Melanie, Bird Robert, Kuter David J
机构信息
Division of Hematology, Mayo Clinic. USA
Center for Hematology, Massachusetts General Hospital, USA.
出版信息
Haematologica. 2016 Dec;101(12):e476-e478. doi: 10.3324/haematol.2016.151886. Epub 2016 Sep 1.
Abstract
摘要
相似文献
1
Remissions after long-term use of romiplostim for immune thrombocytopenia.
Haematologica. 2016 Dec;101(12):e476-e478. doi: 10.3324/haematol.2016.151886. Epub 2016 Sep 1.
2
Treatment of chronic immune thrombocytopenia in children with romiplostim.
Lancet. 2016 Jul 2;388(10039):4-6. doi: 10.1016/S0140-6736(16)00589-4. Epub 2016 Apr 18.
3
Comment on: Use of thrombopoietin receptor agonist (romiplostim) in neonatal autoimmune thrombocytopenia due to maternal immune thrombocytopenia.
Pediatr Blood Cancer. 2019 Jun;66(6):e27706. doi: 10.1002/pbc.27706. Epub 2019 Mar 11.
4
Salvage therapy of autoimmune thrombocytopenic purpura revealing non-Hodgkin lymphoma by the thrombopoietin receptor agonist romiplostim.
Br J Haematol. 2012 Jan;156(1):145-7. doi: 10.1111/j.1365-2141.2011.08825.x. Epub 2011 Aug 16.
5
Restored platelet function after romiplostim treatment in a patient with immune thrombocytopenic purpura.
Br J Haematol. 2010 May;149(4):625-8. doi: 10.1111/j.1365-2141.2010.08092.x. Epub 2010 Feb 8.
6
Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia.
Br J Haematol. 2013 Oct;163(2):286-9. doi: 10.1111/bjh.12483. Epub 2013 Jul 17.
7
Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia.
Transfusion. 2016 Jan;56(1):73-9. doi: 10.1111/trf.13336. Epub 2015 Sep 24.
8
Plateletpheresis for postsplenectomy rebound thrombocytosis in a patient with chronic immune thrombocytopenic purpura on romiplostim.
J Clin Apher. 2013 Aug;28(4):321-4. doi: 10.1002/jca.21254. Epub 2013 Mar 1.
9
The association of rituximab and a thrombopoietin receptor agonist in high-risk refractory immune thrombocytopenic purpura.
Blood Transfus. 2015 Oct;13(4):694-5. doi: 10.2450/2015.0325-14. Epub 2015 Apr 21.
10
Use of a thrombopoietin mimetic for chronic immune thrombocytopenic purpura in pregnancy.
Obstet Gynecol. 2013 Aug;122(2 Pt 2):483-485. doi: 10.1097/AOG.0b013e31828d5b56.
引用本文的文献
1
Thrombopoietin, the Primary Regulator of Platelet Production: From Mythos to Logos, a Thirty-Year Journey.
Biomolecules. 2024 Apr 18;14(4):489. doi: 10.3390/biom14040489.
2
Cost-effectiveness of second-line therapies in adults with chronic immune thrombocytopenia.
Am J Hematol. 2023 Jan;98(1):122-130. doi: 10.1002/ajh.26497. Epub 2022 Feb 24.
3
Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendations.
Ther Adv Hematol. 2021 Oct 9;12:20406207211048361. doi: 10.1177/20406207211048361. eCollection 2021.
4
Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method.
Res Pract Thromb Haemost. 2020 Dec 8;5(1):69-80. doi: 10.1002/rth2.12457. eCollection 2021 Jan.
5
Updated international consensus report on the investigation and management of primary immune thrombocytopenia.
Blood Adv. 2019 Nov 26;3(22):3780-3817. doi: 10.1182/bloodadvances.2019000812.
6
Primary immune thrombocytopenia (ITP) treated with romiplostim in routine clinical practice: retrospective study from the United Kingdom ITP Registry.
Eur J Haematol. 2019 May;102(5):416-423. doi: 10.1111/ejh.13221. Epub 2019 Mar 7.
本文引用的文献
1
Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study.
Br J Haematol. 2016 Jan;172(2):262-73. doi: 10.1111/bjh.13827. Epub 2015 Nov 5.
2
Feasibility of romiplostim discontinuation in adult thrombopoietin-receptor agonist responsive patients with primary immune thrombocytopenia: an observational retrospective report in real life clinical practice.
Hematol Rep. 2015 Feb 24;7(1):5673. doi: 10.4081/hr.2015.5673.
3
Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia.
Am J Hematol. 2015 Mar;90(3):E40-3. doi: 10.1002/ajh.23900. Epub 2015 Jan 16.
4
The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study.
Br J Haematol. 2014 Jun;165(6):865-9. doi: 10.1111/bjh.12888. Epub 2014 Apr 12.
5
Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy.
Br J Haematol. 2013 May;161(3):411-23. doi: 10.1111/bjh.12260. Epub 2013 Feb 22.
6
Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents.
Br J Haematol. 2011 Oct;155(2):248-55. doi: 10.1111/j.1365-2141.2011.08845.x. Epub 2011 Sep 9.
7
The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia.
Blood. 2011 Apr 21;117(16):4190-207. doi: 10.1182/blood-2010-08-302984. Epub 2011 Feb 16.
8
Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production.
Br J Haematol. 2009 Sep;146(6):585-96. doi: 10.1111/j.1365-2141.2009.07717.x. Epub 2009 May 14.
9
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.
Blood. 2009 Mar 12;113(11):2386-93. doi: 10.1182/blood-2008-07-162503. Epub 2008 Nov 12.
10
Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP.
Blood. 2009 Mar 5;113(10):2161-71. doi: 10.1182/blood-2008-04-150078. Epub 2008 Nov 3.
Zotero 插件